Tazarotene - Generic Drug Details

What are the generic drug sources for tazarotene and what is the scope of patent protection?

Tazarotene is the generic ingredient in five branded drugs marketed by Mayne Pharma, Almirall, Cosette Pharms Nc, Fougera Pharms Inc, Padagis Israel, Solaris Pharma Corp, Sun Pharma Canada, and Bausch, and is included in fourteen NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Tazarotene has fifty-six patent family members in twenty-four countries.

There are eight drug master file entries for tazarotene. Ten suppliers are listed for this compound.

Summary for tazarotene

International Patents:	56
US Patents:	6
Tradenames:	5
Applicants:	8
NDAs:	14
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	89
Clinical Trials:	55
Patent Applications:	7,577
Drug Prices:	Drug price trends for tazarotene
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for tazarotene
What excipients (inactive ingredients) are in tazarotene?	tazarotene excipients list
DailyMed Link:	tazarotene at DailyMed

See drug prices for tazarotene

Recent Clinical Trials for tazarotene

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Rosacea Society	NA
Duke University	NA
Assiut University	PHASE4

See all tazarotene clinical trials

Pharmacology for tazarotene

Drug Class

Retinoid

Anatomical Therapeutic Chemical (ATC) Classes for tazarotene

D05AX	Other antipsoriatics for topical use
D05A	ANTIPSORIATICS FOR TOPICAL USE
D05	ANTIPSORIATICS
D	Dermatologicals

Paragraph IV (Patent) Challenges for TAZAROTENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARAZLO	Topical Lotion	tazarotene	0.045%	211882	1	2022-05-12

US Patents and Regulatory Information for tazarotene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000	AB	RX	Yes	Yes
Padagis Israel	TAZAROTENE	tazarotene	GEL;TOPICAL	213079-001	Apr 25, 2023	AB	RX	No	No
Sun Pharma Canada	TAZAROTENE	tazarotene	CREAM;TOPICAL	208258-001	Apr 3, 2017	AB	RX	No	No
Cosette Pharms Nc	TAZAROTENE	tazarotene	CREAM;TOPICAL	208662-001	Dec 22, 2017	AB	RX	No	No
Mayne Pharma	FABIOR	tazarotene	AEROSOL, FOAM;TOPICAL	202428-001	May 11, 2012		RX	Yes	Yes			Y

Expired US Patents for tazarotene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997
Almirall	AVAGE	tazarotene	CREAM;TOPICAL	021184-003	Sep 30, 2002
Almirall	TAZORAC	tazarotene	CREAM;TOPICAL	021184-002	Sep 29, 2000
Almirall	TAZORAC	tazarotene	GEL;TOPICAL	020600-001	Jun 13, 1997
Bausch	ARAZLO	tazarotene	LOTION;TOPICAL	211882-001	Dec 18, 2019

International Patents for tazarotene

Country	Patent Number	Title	Estimated Expiration
Australia	2010217190
Brazil	PI1008037
Canada	2753497
Chile	2011002053
China	102438590

Supplementary Protection Certificates for tazarotene

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0031058	98C0008	Belgium		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: NL22604 19970922; FIRST REGISTRATION: DE - 37393.00.00 19961203
0284288	12/1998	Austria		PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
0284288	SPC/GB98/002	United Kingdom		PRODUCT NAME: TAZAROTENE : ETHYL 6-(2-(4,4-DIMETHYLTHIOCHROMAN-6-YL) ETHYNYL) NICOTINOATE; REGISTERED: DE 37393.00.00 19961203; DE 37393.01.00 19961203; UK 00426/0097 19970730; UK 00426/0096 19970730

TAZAROTENE market dynamics and financial trajectory: pricing, demand drivers, competition, and exclusivity/patent impact

Last updated: July 26, 2026

Tazarotene is a topical retinoid for acne and psoriasis, with pricing and demand anchored to generic penetration and formularies. Financial trajectory is shaped less by patent-driven premium economics and more by unit-volume stability, payer reimbursement, and competition across branded and generic tazarotene creams and gels. The market is also sensitive to drug-formulary positioning for dermatology indications, channel mix shifts toward generics, and product switching within topical retinoid classes.

What tazarotene products drive the market and how do they compare commercially?

Brand vs generic revenue reality

Tazarotene is widely marketed as generics in the U.S., which compresses pricing over time and drives revenue toward higher volume and better formulary placement. Commercial performance tends to track:

• Ingredient- and formulation-specific substitution (cream vs gel)
• NDC/channel concentration (major distributors and retail scripts)
• Payer design and prior authorization usage for topical dermatology regimens

Key marketed tazarotene formats (commercially relevant)

Tazarotene commercial demand is typically segmented by:

• Acne: commonly 0.1% gel and 0.1% cream products
• Plaque psoriasis: commonly 0.05% and 0.1% cream/gels
• Strength and vehicle: bioavailability differences and tolerability often determine patient and prescriber preference, which impacts switching resistance even after generic entry

How have pricing and reimbursement dynamics evolved for tazarotene?

The generic pricing mechanism

Once multiple generic manufacturers establish supply, tazarotene pricing usually follows the standard topical generic pattern:

• Wholesale acquisition cost and reimbursement rates drop as acquisition prices converge
• Gross-to-net widens less than for biologics and oral brands but still reflects rebates, chargebacks, and channel incentives
• Net revenue becomes tightly coupled to script volume rather than ASP premium

Payer incentives and formulary strategy

Market dynamics in topical dermatology usually come down to payer strategy:

• Preferred generic lists reduce the ability for branded products to sustain price
• Step edits or prior authorization are more common when payers seek cost containment across retinoids
• Combination regimen coverage (for example, retinoid plus anti-inflammatory or antimicrobial topicals) can increase overall adherence and product persistence

What demand drivers determine tazarotene unit growth or decline?

Indication mix and seasonal patterns

• Acne: seasonal variability can exist, driven by adherence and dermatology visit patterns, but growth is usually incremental rather than cyclical
• Plaque psoriasis: demand is steadier because patients often require continuous or maintenance regimens

Prescriber and patient selection

Topical retinoids face behavioral friction:

• Irritation and dryness are common adverse effects
• Tolerability support (moisturizers, gradual titration) affects persistence
• Vehicle choice (gel vs cream) drives real-world adherence

Retail vs specialty channel

Tazarotene is predominantly retail, but dermatology clinics and payers influence:

• Specialty pharmacy use is less common than for biologics, but clinic dispensing and formularies still alter channel mix
• Prior authorization design can shift patients toward covered strengths/vehicles

How does competition in topical retinoids affect tazarotene’s financial trajectory?

Substitution within retinoid class

Tazarotene competes for topical retinoid share with:

• Other retinoids (tretinoin, adapalene, tazarotene derivatives where available)
• Vehicles that reduce irritation and improve adherence (cream/gel engineering matters in practice)

Even with generic tazarotene availability, competitors can win through:

• Formulary preference by strength and vehicle
• Better payer contracting terms for specific generic SKUs
• Clinical positioning for tolerability and ease of use

Competitive outcome pattern

For a generic-heavy ingredient like tazarotene, the usual financial trajectory is:

• Flat-to-moderate unit volume changes
• Sustained or declining ASP (net price)
• Margin stability only if manufacturers maintain scale, supply reliability, and lower COGS

When does tazarotene lose exclusivity and how does that map to financial inflection?

A complete exclusivity timeline requires Orange Book patent/marketing exclusivity data tied to the specific approved NDA(s) and strengths. Without that dataset, a precise “lose exclusivity” date cannot be stated.

What the market typically shows around exclusivity cliffs

In topical generics, key financial inflection points usually align with:

• Initial generic launches and subsequent multi-manufacturer supply increases
• Price erosion waves as reimbursement adjusts to prevailing generic WAC and negotiated net prices
• Contracting-driven SKU substitution that accelerates after additional entrants

What is the Orange Book status of tazarotene and what patents protect its products?

A complete Orange Book status and patent list requires the specific NDA numbers, patent identifiers, and expiration dates. Without that, a patent-count and expiration schedule cannot be produced accurately.

What to expect from an ingredient-level estate

For older topical retinoids, the practical patent landscape usually consists of:

• Formulation/vehicle patents (stability, penetration, tolerability)
• Method-of-use patents (indication-specific regimens)
• Process patents (manufacturing method improvements)
• Composition-of-matter coverage that often expires earlier than vehicle- or use-specific patents

What generic entry risks exist for tazarotene (Paragraph IV) and what would they mean for revenue?

A Paragraph IV risk assessment requires filed ANDA details (applicant, submission type, certifications, and current litigation). Without those, a correct identification of entry-risk companies and dates cannot be provided.

Revenue impact if additional ANDAs enter

For a generic-dominant product, incremental ANDA approvals typically produce:

• Additional price compression and rebate pressure
• Increased competitive intensity for contracting
• Margin compression unless the entrant achieves cost leadership

What tazarotene patent litigation affects market entry and settlements?

Patent litigation timelines require court docket numbers, patents-in-suit, and settlement terms. Without that, it is not possible to map litigation to market-entry timing with accuracy.

What does FDA regulatory status imply for commercialization of tazarotene?

Approval basis and lifecycle impact

Tazarotene’s commercial continuity is usually driven by:

• Ongoing maintenance of generic manufacturing and labeling
• Safety communications that may influence prescribing behavior but typically do not stop supply
• Vehicle-level labeling and strength distinctions that determine interchangeable substitution

Risk signals in dermatology topicals

Even without a binding regulatory “trigger,” dermatology products face:

• Labeling sensitivity around irritation and use instructions
• Steady market demand but patient adherence constraints that influence real-world utilization

How do manufacturing and supply dynamics influence tazarotene availability and margins?

Ingredient and process constraints

For generics, manufacturing economics drive competitiveness:

• Cost-effective API sourcing and consistent formulation performance
• Scale efficiencies across multiple SKUs
• Quality and bioequivalence execution that reduces supply interruptions

Supply stability as a pricing lever

When supply constraints occur, wholesalers and payers may temporarily lift realized net prices, but for mature topical generics, the default pattern remains:

• Rapid normalization after capacity returns
• Ongoing price pressure from additional entrants

Which geographies matter most for tazarotene’s financial trajectory?

U.S.-centric economics

For a mature topical retinoid, the highest monetization and volume density typically concentrate in:

• The U.S. retail market via formulary and generic substitution
• Regionally differentiated reimbursement design and uptake of generics in EU/UK markets

A precise geographic revenue split cannot be stated without financial disclosures per jurisdiction.

How does tazarotene’s financial trajectory compare with other topical acne and psoriasis therapies?

Shared pattern across topical dermatology generics

Against branded biologics or novel small molecules:

• Topical retinoids show lower unit-dollar but higher volume stability
• Competitive intensity remains constant because generics and substitutes enter as opportunities open
• Growth is usually achieved by strength/vehicle switching rather than net-new indication creation

Competitive comparison logic

A defensible comparison requires specific competitor brands/generics, but the overarching benchmark for tazarotene is:

• Price erosion risk is high due to generic latitude
• Demand destruction is limited if intolerance rates are managed and adherence remains acceptable

What commercial strategies sustain tazarotene revenue amid generic pressure?

SKU and vehicle optimization

Manufacturers maintain relevance through:

• Preferred strength and vehicle targeting to match payer policies
• Tolerability-oriented formulation tweaks that improve adherence (where permitted)
• Supply assurance for high-volume NDCs

Contracting and formulary access

Sustaining net revenue in topical generics depends on:

• Managed care contracting that preserves share
• Pharmacy benefit design that discourages non-preferred switching into cheaper but less preferred vehicles
• Retail promotions are less decisive than formulary status

Key Takeaways

• Tazarotene’s financial trajectory is driven primarily by generic penetration, formulary positioning, and vehicle-specific substitution rather than premium pricing.
• Unit demand is relatively stable because acne and plaque psoriasis are chronic and topical adherence supports ongoing use, but irritation-related persistence risks limit growth.
• Competition within topical retinoids and generic pricing pressure typically compress ASP and shift revenue toward volume and contracting performance.
• A precise exclusivity and patent-expiration timeline requires Orange Book/NDA-level patent data; generic entry timing and Paragraph IV risk require ANDA litigation and certification datasets.

FAQs

1. What generic tazarotene launches usually cause the biggest price drops?
   Large multi-manufacturer entries into the same strength and vehicle with parallel contracting typically drive the fastest net-price compression.

2. Does tazarotene gel or cream have different formulary outcomes?
   Yes. Payer preferred lists often favor specific vehicles by SKU-level negotiated prices and substitution rules.

3. How sensitive is tazarotene demand to dermatology visit volume?
   Moderately. Script volumes track visits and adherence, but chronic use reduces pure seasonality effects.

4. What adverse-effect management most influences tazarotene persistence?
   Irritation control via gradual titration and supportive skin care improves continuation, which supports stable revenue.

5. How do new competitors in topical retinoids affect tazarotene share?
   They typically take share through formulary preference, tolerability narratives, and vehicle-level contracting that redirects prescribing.

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Database).
2. FDA. Drug Approval Package(s) and labeling for tazarotene-containing products. U.S. Food and Drug Administration. (Database).